oxidopamine has been researched along with Disease Exacerbation in 41 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of these, neuroinflammation is one candidate that appears to accumulate more support with each passing year." | 2.46 | Modeling neuroinflammatory pathogenesis of Parkinson's disease. ( Barnum, CJ; Tansey, MG, 2010) |
| " One of the hallmarks of the disease is the toxic accumulation of proteins within susceptible neurons due to major impairment in the degradation/clearance protein systems." | 1.43 | Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease. ( Alberch, J; Altas, B; Canal, M; Kawabe, H; Malagelada, C; Man, HY; Martín-Flores, N; Pérez-Sisqués, L; Romaní-Aumedes, J, 2016) |
| "Parkinson's disease is a neurodegenerative disorder with uncertain aetiology and ill-defined pathophysiology." | 1.35 | Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. ( Ferrari, CC; Pitossi, FJ; Pott Godoy, MC; Sarchi, MI; Tarelli, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.44) | 18.2507 |
| 2000's | 16 (39.02) | 29.6817 |
| 2010's | 19 (46.34) | 24.3611 |
| 2020's | 5 (12.20) | 2.80 |
| Authors | Studies |
|---|---|
| Iyer, V | 1 |
| Venkiteswaran, K | 1 |
| Savaliya, S | 1 |
| Lieu, CA | 1 |
| Handly, E | 1 |
| Gilmour, TP | 1 |
| Kunselman, AR | 1 |
| Subramanian, T | 1 |
| Minaei, A | 2 |
| Haghdoost-Yazdi, H | 2 |
| Vergara, F | 1 |
| Sardi, NF | 1 |
| Pescador, AC | 1 |
| Guaita, GO | 1 |
| Jark Stern, CA | 1 |
| Chichorro, JG | 1 |
| Fischer, L | 1 |
| Hou, YF | 1 |
| Shan, C | 1 |
| Zhuang, SY | 1 |
| Zhuang, QQ | 1 |
| Ghosh, A | 1 |
| Zhu, KC | 1 |
| Kong, XK | 1 |
| Wang, SM | 1 |
| Gong, YL | 1 |
| Yang, YY | 1 |
| Tao, B | 1 |
| Sun, LH | 1 |
| Zhao, HY | 1 |
| Guo, XZ | 1 |
| Wang, WQ | 1 |
| Ning, G | 1 |
| Gu, YY | 1 |
| Li, ST | 1 |
| Liu, JM | 1 |
| Wang, Y | 1 |
| Gu, L | 1 |
| Yang, HM | 1 |
| Zhang, H | 1 |
| Sarookhani, MR | 1 |
| Rajaei, F | 1 |
| Zhang, W | 1 |
| Zhang, L | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Huotarinen, A | 1 |
| Penttinen, AM | 1 |
| Bäck, S | 1 |
| Voutilainen, MH | 1 |
| Julku, U | 1 |
| Piepponen, TP | 1 |
| Männistö, PT | 1 |
| Saarma, M | 1 |
| Tuominen, R | 1 |
| Laakso, A | 1 |
| Airavaara, M | 1 |
| Park, SE | 2 |
| Song, KI | 2 |
| Kim, H | 1 |
| Chung, S | 1 |
| Youn, I | 2 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Morris, GP | 1 |
| Vissel, B | 1 |
| Xu, R | 1 |
| Zhou, Y | 1 |
| Fang, X | 1 |
| Lu, Y | 2 |
| Li, J | 1 |
| Zhang, J | 1 |
| Deng, X | 1 |
| Li, S | 1 |
| Horvathova, L | 2 |
| Tillinger, A | 2 |
| Sivakova, I | 1 |
| Mikova, L | 1 |
| Mravec, B | 2 |
| Bucova, M | 1 |
| Suh, JK | 1 |
| Hwang, D | 1 |
| Ip, CW | 1 |
| Beck, SK | 1 |
| Volkmann, J | 1 |
| Canal, M | 1 |
| Martín-Flores, N | 1 |
| Pérez-Sisqués, L | 1 |
| Romaní-Aumedes, J | 1 |
| Altas, B | 1 |
| Man, HY | 1 |
| Kawabe, H | 1 |
| Alberch, J | 1 |
| Malagelada, C | 1 |
| Padova, A | 1 |
| Ambrosi, G | 1 |
| Kustrimovic, N | 1 |
| Siani, F | 1 |
| Rasini, E | 1 |
| Cerri, S | 1 |
| Ghezzi, C | 1 |
| Dicorato, G | 1 |
| Caputo, S | 1 |
| Marino, F | 1 |
| Cosentino, M | 1 |
| Blandini, F | 1 |
| Cui, LB | 1 |
| Li, BW | 1 |
| Jin, XH | 1 |
| Zhao, L | 1 |
| Shi, J | 1 |
| Barnum, CJ | 1 |
| Tansey, MG | 1 |
| Kikuchi, Y | 1 |
| Yasuhara, T | 2 |
| Agari, T | 1 |
| Kondo, A | 1 |
| Kuramoto, S | 1 |
| Kameda, M | 1 |
| Kadota, T | 1 |
| Baba, T | 1 |
| Tajiri, N | 1 |
| Wang, F | 1 |
| Tayra, JT | 1 |
| Liang, H | 1 |
| Miyoshi, Y | 1 |
| Borlongan, CV | 2 |
| Date, I | 1 |
| Gambhir, H | 1 |
| Mathur, R | 1 |
| Behari, M | 1 |
| Hsieh, TH | 1 |
| Chen, JJ | 1 |
| Chen, LH | 1 |
| Chiang, PT | 1 |
| Lee, HY | 1 |
| Peng, Y | 1 |
| Yin, SM | 1 |
| Yu, DQ | 1 |
| Xu, H | 1 |
| Dong, FY | 1 |
| Tang, J | 1 |
| Sun, YP | 1 |
| Zhang, WQ | 1 |
| Meng, T | 1 |
| Zheng, ZH | 1 |
| Liu, TT | 1 |
| Lin, L | 1 |
| Tillerson, JL | 1 |
| Cohen, AD | 1 |
| Caudle, WM | 1 |
| Zigmond, MJ | 1 |
| Schallert, T | 1 |
| Miller, GW | 1 |
| Eslamboli, A | 1 |
| Baker, HF | 1 |
| Ridley, RM | 1 |
| Annett, LE | 1 |
| Bergstrom, BP | 1 |
| Garris, PA | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Carta, M | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Ariano, MA | 1 |
| Grissell, AE | 1 |
| Littlejohn, FC | 1 |
| Buchanan, TM | 1 |
| Elsworth, JD | 1 |
| Collier, TJ | 1 |
| Steece-Collier, K | 1 |
| Truong, L | 1 |
| Allbutt, H | 1 |
| Kassiou, M | 1 |
| Henderson, JM | 1 |
| Carvey, PM | 1 |
| Punati, A | 1 |
| Newman, MB | 1 |
| Hara, K | 1 |
| Sethi, KD | 1 |
| Morgan, JC | 1 |
| Breit, S | 1 |
| Bouali-Benazzouz, R | 1 |
| Popa, RC | 1 |
| Gasser, T | 1 |
| Benabid, AL | 1 |
| Benazzouz, A | 1 |
| Zold, CL | 1 |
| Larramendy, C | 1 |
| Riquelme, LA | 1 |
| Murer, MG | 1 |
| Richter, F | 1 |
| Hamann, M | 1 |
| Richter, A | 1 |
| Pott Godoy, MC | 1 |
| Tarelli, R | 1 |
| Ferrari, CC | 1 |
| Sarchi, MI | 1 |
| Pitossi, FJ | 1 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Costantini, LC | 1 |
| Cole, D | 1 |
| Chaturvedi, P | 1 |
| Isacson, O | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Wang, L | 1 |
| Muramatsu, S | 1 |
| Ikeguchi, K | 1 |
| Fujimoto, K | 1 |
| Okada, T | 1 |
| Mizukami, H | 1 |
| Hanazono, Y | 1 |
| Kume, A | 1 |
| Urano, F | 1 |
| Ichinose, H | 1 |
| Nagatsu, T | 1 |
| Nakano, I | 1 |
| Ozawa, K | 1 |
2 reviews available for oxidopamine and Disease Exacerbation
| Article | Year |
|---|---|
Modeling neuroinflammatory pathogenesis of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Dopamine; Humans; Inflammation; Lipopolysaccha | 2010 |
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Disease Models, Animal; Disease Progre | 2006 |
39 other studies available for oxidopamine and Disease Exacerbation
| Article | Year |
|---|---|
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Foreb | 2021 |
Dexmedetomidine attenuates the induction and reverses the progress of 6-hydroxydopamine- induced parkinsonism; involvement of K
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Pr | 2019 |
Contribution of mesolimbic dopamine and kappa opioid systems to the transition from acute to chronic pain.
Topics: Acute Pain; Analgesics, Opioid; Animals; Chronic Pain; Dinoprostone; Disease Progression; Dopamine; | 2020 |
Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; F | 2021 |
Cystic fibrosis transmembrane conductance regulator-associated ligand protects dopaminergic neurons by differentially regulating metabotropic glutamate receptor 5 in the progression of neurotoxin 6-hydroxydopamine-induced Parkinson's disease model.
Topics: Animals; Cell Line; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Dopami | 2021 |
Hydrogen sulfide attenuates induction and prevents progress of the 6-hydroxydopamine-induced Parkinsonism in rat through activation of ATP-sensitive potassium channels and suppression of ER stress.
Topics: Animals; Disease Progression; Endoplasmic Reticulum Stress; Gasotransmitters; Hydrogen Sulfide; KATP | 2021 |
Time course study of fractional anisotropy in the substantia nigra of a parkinsonian rat model induced by 6-OHDA.
Topics: Animals; Apomorphine; Diffusion Tensor Imaging; Disease Progression; Dopamine Agonists; Gliosis; Imm | 2017 |
Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Corpus Striatum; Deep Brain S | 2018 |
Graded 6-OHDA-induced dopamine depletion in the nigrostriatal pathway evokes progressive pathological neuronal activities in the subthalamic nucleus of a hemi-parkinsonian mouse.
Topics: Action Potentials; Animals; Cell Death; Disease Progression; Dopamine; Dopaminergic Neurons; Dose-Re | 2018 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progressio | 2019 |
The possible mechanism of Parkinson's disease progressive damage and the preventive effect of GM1 in the rat model induced by 6-hydroxydopamine.
Topics: Animals; bcl-2-Associated X Protein; Brain; Calcium; Calmodulin; Disease Progression; G(M1) Ganglios | 2014 |
Chemical sympathectomy increases neutrophil-to-lymphocyte ratio in tumor-bearing rats but does not influence cancer progression.
Topics: Animals; Body Weight; Disease Models, Animal; Disease Progression; Erythrocytes; Kaplan-Meier Estima | 2015 |
A time-course study of behavioral and electrophysiological characteristics in a mouse model of different stages of Parkinson's disease using 6-hydroxydopamine.
Topics: Action Potentials; Animals; Body Weight; Disease Progression; Immunohistochemistry; Male; Medial For | 2015 |
Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Animals; Bone Marrow Transplantation; Corpus Striatum; Disease Progression; Dopaminergic Neurons; Ho | 2015 |
Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Cells, Cultured; Cerebellar Cortex; Disease Progression; Female; H | 2016 |
Sympathectomized tumor-bearing mice survive longer but develop bigger melanomas.
Topics: Animals; Disease Progression; Injections, Intraperitoneal; Male; Melanoma; Mice; Mice, Inbred C57BL; | 2016 |
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat.
Topics: Adaptive Immunity; Animals; Antigens, CD; Astrocytes; Corpus Striatum; Disease Models, Animal; Disea | 2017 |
Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Intracellular Signaling Peptides and Proteins; | 2010 |
Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Basal Ganglia; Behavior, Animal; Biomarkers; Brain; Deoxyguano | 2011 |
Progressive impairment in motor skill learning at 12 and 20 weeks post 6-OHDA- SNc lesion in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Disease Progression; Learning; Male; Motor Activi | 2011 |
Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion.
Topics: Analysis of Variance; Animals; Apomorphine; Disease Models, Animal; Disease Progression; Functional | 2011 |
[The reduced antioxidation ability in the serum in the early Parkinson's disease rats].
Topics: Animals; Disease Progression; Dopaminergic Neurons; Free Radical Scavengers; Hydroxyl Radical; Male; | 2011 |
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression; | 2012 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.
Topics: Animals; Behavior, Animal; Callithrix; Cell Count; Corpus Striatum; Disability Evaluation; Disease M | 2003 |
"Passive stabilization" of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Electric Stimulatio | 2003 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Corpus Striatum; Disease Models, Animal; Disease Progressio | 2005 |
Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
Topics: Analysis of Variance; Animals; Cell Death; Diagnosis; Disease Models, Animal; Disease Progression; D | 2006 |
Increased 8-OHdG levels in the urine, serum, and substantia nigra of hemiparkinsonian rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Biomarkers; Deoxyguanosine; Disease Progression; Neurotoxins; | 2007 |
Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat.
Topics: Animals; Corpus Striatum; Disease Progression; Dopamine; Electrophysiology; Globus Pallidus; Male; M | 2007 |
Distinct changes in evoked and resting globus pallidus activity in early and late Parkinson's disease experimental models.
Topics: Action Potentials; Animals; Behavior, Animal; Brain Mapping; Disease Models, Animal; Disease Progres | 2007 |
Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.
Topics: Animals; Cell Count; Disease Models, Animal; Disease Progression; Dopamine; Dose-Response Relationsh | 2008 |
Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.
Topics: Animals; Cells, Cultured; Dexamethasone; Disease Models, Animal; Disease Progression; Enzyme-Linked | 2008 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine; Dopamine Agent | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Topics: Animals; Dependovirus; Disease Progression; Dopamine; Gene Expression; Genetic Therapy; Genetic Vect | 2002 |